Personalized medicine gaining ground in U.S., Europe, report finds

http://www.healthcaredive.com/news/personalized-medicine-gaining-ground-in-us-europe-report-finds/418775/

Personalized medicine is already having a measurable impact on patient outcomes and will play a strong role in healthcare facilities in the next two years, anew report stated.

http://www.healthcaredive.com/news/precision-medicine-initiative-sets-privacy-principles/409461/

 

Zooming In On Millennials

http://khn.org/news/zooming-in-on-millennials/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202016-05-10%20Healthcare%20Dive%20%5Bissue:5833%5D&utm_term=Healthcare%20Dive

Dr. Craig McDougall and his patient Amy Cannon reviewed her latest lab results. Cannon, 45, has high cholesterol and high blood pressure but McDougall told her she was on the right track. She had lost 30 pounds and her blood sugar level had dropped.

Zoom, which serves patients in Portland, Seattle and Vancouver, Washington, is trying to buck the traditional health care system by offering what it bills as convenient, affordable care in a hip and user-friendly environment. The retail clinics, painted a vibrant turquoise, are stylish and simple. The prices are posted on the walls.

Performance measures put heat on hospitals

http://www.healthcaredive.com/news/performance-measures-put-heat-on-hospitals/418477/

This year has seen a bevy of new programs and initiatives aimed at moving providers toward a value-based model of care.

U.S. inches closer to national single-payer plan conversation

http://www.healthcaredive.com/news/us-inches-closer-to-national-single-payer-plan-conversation/418939/

 

Soon-Shiong’s NantHealth files $92M IPO

http://www.healthcaredive.com/news/soon-shiongs-nanthealth-files-92m-ipo/418877/

NantHealth, a personalized medicine and IT company founded by Dr. Patrick Soon-Shiong, has filed for a $92 million initial public offering (IPO).

The Killer Disease on the Rise that Could Explode Health Costs

http://www.thefiscaltimes.com/2016/05/05/Killer-Disease-Rise-Could-Explode-Health-Costs?utm_campaign=541c47950e351dbe08037e5f&utm_source=boomtrain&utm_medium=email&bt_alias=eyJ1c2VySWQiOiJhODE3YzA4MS1jNGE1LWZmN2UtY2IyNC0xNzQ1NTc5MWViNmQifQ%3D%3D

Hepatitis-C is a serious liver infection caused by an often lethal virus, and it spreads from one person to another through contact with blood, including blood transfusions and shared needles. Gilead Sciences boasts that its two leading biologic medications have a cure rate of as high as 95 percent, in comparison with 40 percent for older, less advanced treatments. But Sovaldi and Harvoni can cost between $83,000 and $95,000 retail for a full course of treatment.